FDA WARNS AGAINST COMPOUNDING LYME DRUG

Published Online: Friday, September 1, 2006

The FDA has called on pharmacists to stop compounding a treatment for Lyme disease that has been linked to at least one patient death and a number of suspected illnesses. The drug, called bismacine or chromocine, is mixed individually by pharmacists for use by injection to treat the symptoms of the tick-borne bacterial disease. According to the FDA, the substance contains high amounts of the heavy metal bismuth and is unapproved for use by humans. Agency officials said that the substance is sometimes prescribed by "alternative health doctors."



Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues
$auto_registration$
VSEO N/A